Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.75 |
| ▸ | KIT | P10721 | 8/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.64 |
| ▸ | LCK | P06239 | 4/20 | 0.64 |
| ▸ | AXL | P30530 | 4/20 | 0.64 |
| ▸ | FLT3 | P36888 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | STK25 | O00506 | 2/20 | 0.56 |
| ▸ | RIOK3 | O14730 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.56 |
| ▸ | GAK | O14976 | 2/20 | 0.56 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.56 |
| ▸ | MUSK | O15146 | 2/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.56 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4983287 | 0.95 | CSF1R (0.68) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL13105559 | 0.93 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL13096399 | 0.93 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL14542959 | 0.92 | CSF1R (0.62) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL2942044 | 0.91 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL4986321 | 0.91 | CSF1R (0.76) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL13105790 | 0.90 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL14516350 | 0.89 | CSF1R (0.69) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL5181727 | 0.89 | CSF1R (0.75) | CSF1RKITCYP3A4NTRK1LCK | |
| SCHEMBL2940010 | 0.88 | CSF1R (0.64) | CSF1RKITCYP3A4NTRK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-07 | — | — | US | disclosed |
| US-7795279-B2 | Method of inhibiting FLT3 kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7662837-B2 | 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7645755-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | BAUMANN CHRISTIAN ANDREW | 2009-08-06 | — | — | US | disclosed |
| WO-2009058801-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| EP-1898912-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007124369-A2 | METHOD OF INHIBITING C KIT KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256148-A1 | USE OF CFMS INHIBITOR FOR TREATING OR PREVENTING BONE CANCER AND THE BONE LOSS AND BONE PAIN ASSOCIATED WITH BONE CANCER | SOST, CALCB, CALCA | CSF1R 304/4885KIT 873/4885CYP3A4 4421/4885 |
| US-20080051402-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CSF1R 2973/4885KIT 1/4885CYP3A4 4130/4885 |
| US-20090197913-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | CSF1R 3/4885KIT 70/4885CYP3A4 2047/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | CSF1R 149/4885KIT 192/4885CYP3A4 3994/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CSF1R 2973/4885KIT 1/4885CYP3A4 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.